<
 / Physicians

Drug recall and shortage update: Lidocaine 12 mg/dose endotracheal spray

Date

The issue: Odan previously issued a voluntary, type 3 recall for one lot of lidocaine 12 mg/dose endotracheal spray. This recall was due to a potential for the dispenser to leak. Type 3 recalls are defined by Health Canada as unlikely to cause adverse health effects. This recall contributed to a national shortage of the product, which is on backorder until further notice. NH supply remains low and some sites will likely experience stock outs before resupply is available.

Actions: 

  • NH Pharmacy will replace wardstock with unaffected lots wherever possible
  • When unaffected supply is not available and an affected lot must be used to provide clinical care, this memo will be supplied with the product to alert staff
  • Staff should be aware of the potential for leakage and check/prime the lidocaine spray prior to use to assess for leakage
  • Staff are requested to report leakage incidents, should they occur
  • Remaining supply should be reserved as much as possible for use in clinical areas with the most need (i.e. ICU, ambulatory care units)

Potential alternatives: 

  • Lidocaine solution can be administered via atomization device as needed:
    • MADgicâ„¢ Laryngo-Tracheal Mucosal Atomization Device (item number: 5005140)
    • Contact your local Respiratory Therapist or Dana Thomas (Regional Respiratory Practice Lead) for assistance as needed
  • Lidocaine solutions are available in 1% (10 mg/mL), 2% (20 mg/mL), and 4% (40 mg/mL) concentrations

Further information and practice implications.

Share this page